HIT Consultant February 12, 2024
What You Should Know:
– Medicare has significantly expanded access to the Eversense E3 continuous glucose monitoring (CGM) System, a long-lasting and implantable option that offers several advantages over traditional CGMs.
– Medicare has significantly expanded access to the Eversense E3 CGM System, the longest-lasting continuous glucose monitor available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal-only patients, by the first three Medicare Administrative Contractors (MACs).
– The Medicare expansion is expected to benefit millions of Americans who rely on Medicare for their diabetes care. The earliest MAC expansion becomes effective on February 25, 2024, and the companies expect the remaining MACs to finalize their expansion soon.
Long-Lasting CGM System for People with Diabetes
...Today's Sponsors
Today's Sponsor